1,282 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Legacy Solutions LLC

Legacy Solutions LLC purchased a new position in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,282 shares of the company’s stock, valued at approximately $209,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. State Street Corp boosted its position in shares of Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after acquiring an additional 95,856 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the last quarter. Mizuho Securities USA LLC grew its stake in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after buying an additional 194,542 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $156.43 on Wednesday. The business has a 50 day moving average price of $167.70 and a two-hundred day moving average price of $178.44. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The firm has a market cap of $70.05 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Sell-side analysts expect that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ZTS shares. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus target price of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.